REGENERON PHARMACEUTICALS, INC. Proceeds from Long-term Capital Lease Obligations
REGENERON PHARMACEUTICALS, INC. (REGN) reported Proceeds from Long-term Capital Lease Obligations of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermCapitalLeaseObligations · last filed 2020-02-07
- REGENERON PHARMACEUTICALS, INC. proceeds from long-term capital lease obligations for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- REGENERON PHARMACEUTICALS, INC. proceeds from long-term capital lease obligations for fiscal 2017 was $57.00M.
- REGENERON PHARMACEUTICALS, INC. proceeds from long-term capital lease obligations for fiscal 2010 was $47.54M.
| Period end | Proceeds from Long-term Capital Lease Obligations 12 month |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2020-02-07 |
| 2017-12-31 | $57.00M 10-K · filed 2020-02-07 |
| 2010-12-31 | $47.54M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |